Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib

Sorafenib remains the standard care for patients with hepatocellular carcinoma (HCC) even though it has low antitumor efficacy. Protein neddylation is abnormally activated in many types of human cancer. However, whether dysregulation of neddylation is involved in HCC progression and whether targetin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncol Rep
Autors principals: Yang, Zelong, Zhang, Jie, Lin, Xiaotong, Wu, Di, Li, Guixi, Zhong, Chunlian, Fang, Lei, Jiang, Peng, Yin, Liangyu, Zhang, Leida, Bie, Ping, Xie, Chuan-Ming
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2019
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6489087/
https://ncbi.nlm.nih.gov/pubmed/31002342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2019.7098
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars